We serve Chemical Name:1-bromonaphthalen-2-amine CAS:20191-75-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-bromonaphthalen-2-amine
CAS.NO:20191-75-7
Synonyms:1-bromo-2-aminonaphthalene;1-bromo-naphthalen-2-ylamine;2-amino-1-bromonaphthalene;2-amino-1-bromonaphthalin
Molecular Formula:C10H8BrN
Molecular Weight:222.08100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:345.5ºC at 760 mmHg
Density:1.563g/cm3
Index of Refraction:1.718
PSA:26.02000
Exact Mass:220.98400
LogP:3.76570
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-bromo-2-aminonaphthalene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-amino-1-bromonaphthalin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-amino-1-bromonaphthalin Use and application,2-amino-1-bromonaphthalene technical grade,usp/ep/jp grade.
Related News: We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently. 1-bromonaphthalen-2-amine manufacturer The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses. 1-bromonaphthalen-2-amine supplier We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� 1-bromonaphthalen-2-amine vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 1-bromonaphthalen-2-amine factory We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently.
